SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-123807
Filing Date
2023-12-06
Accepted
2023-12-06 07:00:28
Documents
15
Period of Report
2023-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2332261d1_8k.htm   iXBRL 8-K 36755
2 EXHIBIT 4.1 tm2332261d1_ex4-1.htm EX-4.1 67453
3 EXHIBIT 4.2 tm2332261d1_ex4-2.htm EX-4.2 67188
4 EXHIBIT 4.3 tm2332261d1_ex4-3.htm EX-4.3 246816
  Complete submission text file 0001104659-23-123807.txt   669887

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA btai-20231205.xsd EX-101.SCH 3048
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20231205_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20231205_pre.xml EX-101.PRE 22381
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2332261d1_8k_htm.xml XML 3312
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 231468394
SIC: 2834 Pharmaceutical Preparations